Parkinson's Disease
FDA approves first adaptive deep brain stimulation system for Parkinson’s disease
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.
Vistagen receives US patent for nonopioid neuropathic pain therapy
The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment.
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.
FDA approves Onapgo for motor fluctuations in adults with Parkinson’s disease
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.
Anti-inflammatory therapies linked to reduced risk, incidence of Parkinson’s disease
In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.
Dual mobility components for THA may be justified in high-risk patients
KOLOA, Hawaii — Dual mobility components in total hip arthroplasty are a proven concept that decrease dislocation rates in patients at high risk for instability, according to a presenter here.
Wait times for neurology visits longer for patients with MS, epilepsy, Parkinson’s
The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.
Parkinson’s Foundation issues guidelines to ‘avoid preventable harm’ in hospitals
The Parkinson's Foundation has issued new recommendations to improve the standard of care for hospitalization among individuals with Parkinson’s disease.
Michael J. Fox Foundation awards $4.2M to support clinical trial of Parkinson’s skin test
A Phoenix-area medical technology company has received $4.2M grant fromThe Michael J. Fox Foundation for Parkinson’s Research to support a study for a skin test that quantifies abnormal alpha-synuclein in those with Parkinson’s disease.
Partnership to advance customized biomarker assays for range of neurological conditions
ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for companies that advance novel therapeutics for a range of neurological conditions.